PDF(Pubmed)
Abstract：
Since the beginning of the mass immunization of patients with multiple sclerosis (MS), many data on the efficacy and safety of COVID-19 vaccines have been produced. Considering that MS is an autoimmune disease and that some disease-modifying therapies (DMTs) could decrease the antibody response against COVID-19 vaccines, we carried out this retrospective study with the aim to evaluate the safety of these vaccines in terms of AEFI occurrence and the antibody response after MS patients had received the third dose. Two hundred and ten patients (64.8% female; mean age: 46 years) received the third dose of the mRNA-based COVID-19 vaccine and were included in the study. Third doses were administered from October 2021 to January 2022. The majority of patients (n = 193) were diagnosed with RRMS and EDSS values were ≤3.0 in 72.4% of them. DMTs most commonly used by included patients were interferon Beta 1-a, dimethyl fumarate, natalizumab and fingolimod. Overall, 160 patients (68.8% female) experienced 294 AEFIs, of which about 90% were classified as short-term, while 9.2% were classified as long-term. The most commonly reported following the booster dose were pain at the injection site, flu-like symptoms, headache, fever and fatigue. Regarding the immune response, consistently with literature data, we found that patients receiving ocrelizumab and fingolimod had lower IgG titer than patients receiving other DMTs.
摘要：
自从多发性硬化症（MS）患者的大规模免疫接种开始以来，已经产生了许多关于COVID-19疫苗有效性和安全性的数据。考虑到MS是一种自身免疫性疾病，并且某些疾病修饰疗法（DMT）可以降低针对COVID-19疫苗的抗体反应，我们进行了这项回顾性研究,目的是评估这些疫苗在MS患者接受第三剂治疗后的AEFI发生率和抗体应答方面的安全性.二百一十名患者(64.8%为女性；平均年龄：46岁)接受了第三剂基于mRNA的COVID-19疫苗，并被纳入研究。第三剂于2021年10月至2022年1月服用。大多数患者（n=193）被诊断为RRMS，其中72.4％的EDSS值≤3.0。纳入患者最常用的DMT是干扰素β1-a，富马酸二甲酯,那他珠单抗和芬戈莫德。总的来说,160名患者（68.8%为女性）经历了294次AEFI，其中约90%被归类为短期，而9.2%被归类为长期。加强剂量后最常见的报告是注射部位疼痛，流感样症状,头痛,发烧和疲劳。关于免疫反应，与文献数据一致，我们发现,接受奥利珠单抗和芬戈莫德的患者的IgG滴度低于接受其他DMT的患者.
